Laboratorios Farmaceuticos Rovi, S.A. (BME:ROVI)
Spain · Delayed Price · Currency is EUR 59.00
+0.40 (0.68%)
Aug 7, 2026, 1:45 PM CET
BME:ROVI Ratios and Metrics
Market cap in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,997 | 3,248 | 3,220 | 3,120 | 1,925 | 4,091 | |
Market Cap Growth | 10.24% | 0.87% | 3.21% | 62.09% | -52.96% | 94.86% |
Enterprise Value | 2,993 | 3,283 | 3,316 | 3,164 | 1,873 | 3,993 |
Last Close Price | 59.00 | 63.50 | 62.95 | 60.20 | 36.06 | 73.80 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 16.18 | 23.09 | 23.58 | 18.81 | 9.67 | 26.74 |
Forward PE | 20.05 | 21.58 | 19.02 | 19.76 | 12.76 | 25.70 |
PEG Ratio | 1.34 | 2.31 | 1.73 | 13.17 | 1.42 | 0.84 |
PS Ratio | 3.88 | 4.37 | 4.22 | 3.76 | 2.35 | 6.31 |
PB Ratio | 4.18 | 4.89 | 5.63 | 5.78 | 3.70 | 8.69 |
P/TBV Ratio | 4.54 | 5.17 | 5.99 | 6.34 | 3.98 | 9.46 |
P/FCF Ratio | 16.71 | 89.33 | 66.69 | 64.05 | 10.30 | 37.46 |
P/OCF Ratio | 11.83 | 72.96 | 62.32 | 57.55 | 8.10 | 27.38 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 3.87 | 4.42 | 4.34 | 3.81 | 2.29 | 6.16 |
EV/EBITDA Ratio | 18.67 | 16.80 | 17.56 | 13.73 | 6.72 | 19.68 |
EV/EBIT Ratio | 22.20 | 17.66 | 18.49 | 14.37 | 7.32 | 21.99 |
EV/FCF Ratio | 16.68 | 90.29 | 68.69 | 64.96 | 10.02 | 36.56 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.11 | 0.14 | 0.16 | 0.10 | 0.11 | 0 |
Debt / EBITDA Ratio | 0.67 | 0.62 | 0.61 | 0.28 | 0.26 | 0.00 |
Debt / FCF Ratio | 0.88 | 3.35 | 2.37 | 1.34 | 0.39 | 0.01 |
Net Debt / Equity Ratio | -0.03 | 0.04 | 0.15 | 0.07 | -0.10 | -0.21 |
Net Debt / EBITDA Ratio | -0.13 | 0.12 | 0.46 | 0.17 | -0.19 | -0.48 |
Net Debt / FCF Ratio | -0.17 | 0.66 | 1.80 | 0.82 | -0.28 | -0.90 |
Asset Turnover | 0.74 | 0.83 | 0.94 | 0.99 | 1.01 | 0.99 |
Inventory Turnover | 0.56 | 0.85 | 0.86 | 1.05 | 1.08 | 1.12 |
Quick Ratio | 1.05 | 1.52 | 1.00 | 0.84 | 1.04 | 0.52 |
Current Ratio | 2.05 | 3.13 | 3.13 | 2.55 | 2.12 | 2.66 |
Return on Equity (ROE) | 26.58% | 22.33% | 24.33% | 31.98% | 40.24% | 36.25% |
Return on Assets (ROA) | 10.19% | 15.92% | 16.94% | 20.27% | 24.58% | 23.29% |
Return on Invested Capital (ROIC) | 15.15% | 20.81% | 22.07% | 32.33% | 47.08% | 39.96% |
Return on Capital Employed (ROCE) | 16.60% | 25.64% | 28.13% | 37.16% | 45.40% | 36.54% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 7, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 6.18% | 4.33% | 4.24% | 5.32% | 10.34% | 3.74% |
FCF Yield | 5.99% | 1.12% | 1.50% | 1.56% | 9.71% | 2.67% |
Dividend Yield | 1.64% | 2.95% | 3.50% | 4.31% | 2.65% | 0.52% |
Payout Ratio | 25.83% | 68.11% | 82.48% | 81.07% | 25.55% | 13.80% |
Buyback Yield / Dilution | -0.05% | 0.12% | 3.73% | 0.51% | 3.50% | -0.03% |
Total Shareholder Return | 1.58% | 3.07% | 7.23% | 4.83% | 6.14% | 0.48% |